BICO Group AB (publ) (BCCOY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BICO Group AB (publ) (BCCOY) with AI Score 46/100 (Weak). BICO Group AB (publ) operates as a bio convergence company, providing laboratory solutions and bioautomation products to medical, pharmaceutical, and cosmetic industries. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026BICO Group AB (publ) (BCCOY) Healthcare & Pipeline Overview
BICO Group AB (publ) is a bio convergence company providing 3D bioprinting, bioautomation, and laboratory solutions to the medical, pharmaceutical, and cosmetic industries. With a focus on tissue engineering and diagnostics, BICO serves a global market, offering tools and services for regulatory testing and advanced research applications.
Investment Thesis
BICO Group AB (publ) presents a notable research candidate within the bio convergence space. The company's focus on 3D bioprinting and automation solutions caters to the growing demand for advanced tools in the medical, pharmaceutical, and cosmetic industries. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets. The company's gross margin stands at 45.3%. However, the company's negative profit margin of -70.2% and a high beta of 2.77 indicate significant risk. Upcoming catalysts include potential partnerships with pharmaceutical companies and expansion of its bioautomation segment. Investors should monitor the company's ability to achieve profitability and manage its operational costs.
Based on FMP financials and quantitative analysis
Key Highlights
- BICO Group AB (publ) operates in the bio convergence space, merging biology and technology.
- The company's gross margin is 45.3%, indicating a strong ability to control production costs.
- BICO serves the medical, pharmaceutical, and cosmetic industries, providing diversification across healthcare sectors.
- The company's beta is 2.77, indicating high volatility compared to the market.
- BICO Group AB (publ) has a negative profit margin of -70.2%, reflecting ongoing challenges in achieving profitability.
Competitors & Peers
Strengths
- Innovative 3D bioprinting technology
- Strong presence in the research and pharmaceutical sectors
- Comprehensive product portfolio
- Strategic partnerships with leading institutions
Weaknesses
- Negative profit margin
- High beta indicating high volatility
- Limited brand recognition compared to larger competitors
- Dependence on research grants and funding
Catalysts
- Ongoing: Expansion of product portfolio with new bioinks and bioprinting technologies.
- Upcoming: Potential partnerships with pharmaceutical companies for drug discovery applications (2026-Q4).
- Ongoing: Geographic expansion into the Asia-Pacific market.
- Upcoming: Publication of clinical trial results using BICO's technology (2026-Q3).
- Ongoing: Increased adoption of BICO's solutions in personalized medicine.
Risks
- Potential: Intense competition from established players in the laboratory solutions and bioautomation markets.
- Ongoing: Negative profit margin and high operational costs.
- Potential: Economic downturn affecting research funding and capital expenditures.
- Ongoing: Stringent regulatory requirements and compliance costs.
- Potential: Currency risk due to fluctuations in the Swedish Krona (SEK) against the U.S. dollar (USD).
Growth Opportunities
- Expansion into Personalized Medicine: BICO can leverage its 3D bioprinting technology to create personalized medical solutions, such as patient-specific implants and tissues. The personalized medicine market is projected to reach $2.4 billion by 2028, offering significant growth potential. BICO's ability to tailor solutions to individual patient needs provides a competitive advantage. This expansion requires strategic partnerships with hospitals and research institutions.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop new drug screening platforms and accelerate drug discovery processes. The pharmaceutical industry is increasingly adopting advanced technologies to reduce development costs and timelines. BICO's laboratory solutions can enhance drug screening accuracy and efficiency. These partnerships can provide BICO with recurring revenue streams and market validation.
- Geographic Expansion in Asia-Pacific: Expanding its presence in the Asia-Pacific region, where demand for advanced healthcare solutions is growing rapidly. The region's aging population and increasing healthcare expenditure create opportunities for BICO's products and services. Establishing local partnerships and distribution networks is crucial for successful market entry. This expansion can significantly increase BICO's revenue and global market share.
- Development of Advanced Bioinks: Investing in the development of advanced bioinks with improved biocompatibility and functionality. Bioinks are essential for 3D bioprinting and play a critical role in tissue engineering and regenerative medicine. BICO's ability to create bioinks that mimic the natural extracellular matrix can enhance the success of bioprinted tissues and organs. This innovation can attract new customers and solidify BICO's position as a leader in the bio convergence space.
- Integration of Artificial Intelligence (AI): Integrating AI and machine learning technologies into its bioprinting and automation platforms to improve efficiency and accuracy. AI can optimize printing parameters, predict tissue behavior, and automate laboratory processes. This integration can reduce human error and accelerate research and development timelines. The AI in healthcare market is expected to grow significantly, offering BICO a competitive edge.
Opportunities
- Expansion into personalized medicine
- Growing demand for 3D bioprinting in drug discovery
- Geographic expansion in Asia-Pacific
- Development of advanced bioinks
Threats
- Intense competition from established players
- Stringent regulatory requirements
- Economic downturn affecting research funding
- Technological obsolescence
Competitive Advantages
- Proprietary Technology: BICO's patented 3D bioprinting technology and bioinks provide a competitive advantage.
- Established Customer Base: The company has built a strong customer base in the research, pharmaceutical, and healthcare sectors.
- Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies enhance BICO's market position.
- Comprehensive Product Portfolio: BICO offers a wide range of products and services, providing a one-stop solution for customers.
About BCCOY
BICO Group AB (publ), formerly known as Cellink AB, was founded in 2016 and is headquartered in Gothenburg, Sweden. The company operates as a bio convergence entity, offering solutions that bridge biology and technology. BICO serves the medical, pharmaceutical, and cosmetic industries across North America, Europe, Asia, and internationally. The company is structured into two primary segments: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment provides 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments. It also offers related consumables such as bioinks, reagents, microscope lenses, software, and 3D reconstructed human tissues, which are used in regulatory testing. This segment also provides services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. The Bioautomation segment delivers precision dispensing and biosensor technology to industrial customers, as well as diagnostics automation and advanced robotics solutions for the medical and diagnostic sectors. BICO's product offerings also include core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions.
What They Do
- Develops and sells 3D bioprinters for tissue engineering and regenerative medicine.
- Offers hybrid microscopes for advanced cell imaging and analysis.
- Provides single-cell dispensing instruments for precise cell handling.
- Manufactures liquid handling instruments for laboratory automation.
- Supplies bioinks, reagents, and other consumables for bioprinting applications.
- Offers services in 3D cell culture, tissue imaging, and digital pathology.
- Provides precision dispensing and biosensor technology for industrial customers.
- Offers diagnostics automation and advanced robotics solutions for the medical and diagnostic industries.
Business Model
- Sells 3D bioprinters, microscopes, and related instruments to research institutions, pharmaceutical companies, and hospitals.
- Generates revenue from the sale of consumables such as bioinks and reagents.
- Provides services in 3D cell culture, tissue imaging, and digital pathology.
- Offers automation solutions to industrial and medical customers.
Industry Context
BICO Group AB (publ) operates within the medical devices industry, which is experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market for 3D bioprinting is expanding, with applications in drug discovery, tissue engineering, and regenerative medicine. BICO competes with companies such as ACMLF, BRIBF, CYBQF, MLLCF, and NDTP, which offer various laboratory solutions and automation technologies. The industry is characterized by high research and development costs and stringent regulatory requirements. BICO's bio convergence approach positions it to capitalize on the convergence of biology and technology, addressing the needs of the medical, pharmaceutical, and cosmetic industries.
Key Customers
- Research institutions conducting tissue engineering and regenerative medicine research.
- Pharmaceutical companies developing new drugs and therapies.
- Hospitals and medical centers performing tissue repair and replacement procedures.
- Cosmetic companies developing and testing new products.
Financials
Chart & Info
BICO Group AB (publ) (BCCOY) stock price: Price data unavailable
Latest News
No recent news available for BCCOY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCCOY.
Price Targets
Wall Street price target analysis for BCCOY.
MoonshotScore
What does this score mean?
The MoonshotScore rates BCCOY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Maria Forss
CEO
Maria Forss serves as the CEO of BICO Group AB (publ). Her background includes extensive experience in managing and scaling technology-driven companies. She has a proven track record in strategic leadership and operational excellence. She is responsible for overseeing BICO's global operations and driving the company's growth strategy. Her expertise lies in biotechnology and business development, which is crucial for BICO's expansion and innovation in the bio convergence space.
Track Record: Under Maria Forss's leadership, BICO Group AB (publ) has focused on expanding its product portfolio and strengthening its presence in key markets. She has overseen strategic acquisitions and partnerships to enhance the company's technological capabilities and market reach. Her focus on innovation and customer satisfaction has contributed to BICO's growth and success in the bio convergence industry.
BICO Group AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BCCOY is an ADR, meaning it allows U.S. investors to invest in BICO Group AB (publ) without directly dealing with the Gothenburg Stock Exchange. The ADR is denominated in U.S. dollars, simplifying transactions and reporting for U.S. investors.
- Home Market Ticker: Gothenburg Stock Exchange, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BCCO
BCCOY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and transparency compared to exchange-listed companies. These companies may be newly established, financially distressed, or have chosen not to list on a major exchange for various reasons.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of publicly available financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: Low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares without impacting the price.
- Regulatory Uncertainty: OTC stocks are subject to less regulatory oversight compared to exchange-listed stocks, increasing the risk of fraud and manipulation.
- Valuation Challenges: The limited information available makes it difficult to accurately value the company.
- Potential for Delisting: BCCOY could be delisted from the OTC market if it fails to meet certain requirements.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business Operations: BICO Group AB (publ) has been in operation since 2016, indicating a track record of business activity.
- Global Presence: The company operates in North America, Europe, Asia, and internationally, suggesting a broad market reach.
- Audited Financials: While the disclosure level is unknown, any available audited financial statements would be a positive signal.
- Partnerships: Any partnerships with reputable organizations would indicate credibility.
- Industry Recognition: Awards or recognition from industry associations would be a positive sign.
Common Questions About BCCOY
What does BICO Group AB (publ) do?
BICO Group AB (publ) operates as a bio convergence company, providing laboratory solutions and bioautomation products to the medical, pharmaceutical, and cosmetic industries. The company's core offerings include 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and related consumables such as bioinks and reagents. BICO's solutions are used in tissue engineering, regenerative medicine, drug discovery, and diagnostics, serving a global market with a focus on innovation and technological advancement in the healthcare sector.
What do analysts say about BCCOY stock?
Analyst consensus on BCCOY stock is currently unavailable due to limited coverage. Key valuation metrics such as the P/E ratio are not meaningful due to negative earnings. Growth considerations include the company's expansion into new markets and the development of innovative products. Investors should conduct their own due diligence and consider the company's financial performance, competitive landscape, and growth potential before making any investment decisions. There are no recommendations to buy or sell.
What are the main risks for BCCOY?
The main risks for BICO Group AB (publ) include intense competition in the laboratory solutions and bioautomation markets, which could impact market share and profitability. The company's negative profit margin and high operational costs pose a challenge to achieving sustainable profitability. Economic downturns could affect research funding and capital expenditures, reducing demand for BICO's products and services. Stringent regulatory requirements and compliance costs could also increase expenses and delay product development. Currency risk due to fluctuations in the Swedish Krona (SEK) against the U.S. dollar (USD) could impact revenue and earnings.
What are the key factors to evaluate for BCCOY?
BICO Group AB (publ) (BCCOY) currently holds an AI score of 46/100, indicating low score. Key strength: Innovative 3D bioprinting technology. Primary risk to monitor: Potential: Intense competition from established players in the laboratory solutions and bioautomation markets.. This is not financial advice.
How frequently does BCCOY data refresh on this page?
BCCOY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BCCOY's recent stock price performance?
Recent price movement in BICO Group AB (publ) (BCCOY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative 3D bioprinting technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BCCOY overvalued or undervalued right now?
Determining whether BICO Group AB (publ) (BCCOY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BCCOY?
Before investing in BICO Group AB (publ) (BCCOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst consensus is not available due to limited coverage.
- OTC market data may be less reliable than exchange-listed data.